Patents Examined by Minh-Tam Davis
  • Genes from the 20q13 amplicon and their uses
    Patent number: 7455964
    Abstract: The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: November 25, 2008
    Assignees: The Hospital for Sick Children, The Regents of the University of California
    Inventors: Joe W. Gray, Colin Conrad Collins, Soo-in Hwang, Tony Godfrey, David Kowbel, Johanna Rommens
  • Molecules of the card-related protein family and uses thereof
    Patent number: 7452967
    Abstract: Novel CARD-9, CARD-10, or CARD-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-9, CARD-10, or CARD-11 proteins, the invention further provides CARD-9, CARD-10, or CARD-11, fusion proteins, antigenic peptides and anti-CARD-9, CARD-10, or CARD-11 antibodies. The invention also provides CARD-9, CARD-10, or CARD-11 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-9, CARD-10, or CARD-11 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: November 18, 2008
    Assignee: Millenium Pharmaceuticals, Inc.
    Inventor: John Bertin
  • Antibodies that recognize hyperproliferative cells and methods of making and using same
    Patent number: 7446178
    Abstract: The invention relates to antibodies that bind to antigens, such as antigens associated with hyperproliferating cells, and methods of treating hyperproliferative disorders. The invention antibodies are useful for treating hyperproliferative disorders, such as neoplasia.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: November 4, 2008
    Assignee: Shantha West, Inc.
    Inventors: Subhra Chakrabarti, Sonjoy Mukerjee, Mark C. Glassy
  • Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
    Patent number: 7432064
    Abstract: The present invention provides new methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer.
    Type: Grant
    Filed: August 16, 2004
    Date of Patent: October 7, 2008
    Assignee: diaDexus, Inc.
    Inventors: Susana Salceda, Herve Recipon, Robert Cafferkey
  • Id-1 and Id-2 genes and products as markers of epithelial cancer
    Patent number: 7429457
    Abstract: A method for detection and prognosis of breast cancer and other types of cancer. The method comprises detecting expression, if any, for both an Id-1 and an Id-2 genes, or the ratio thereof, of gene products in samples of breast tissue obtained from a patient. When expressed, Id-1 gene is a prognostic indicator that breast cancer cells are invasive and metastatic, whereas Id-2 gene is a prognostic indicator that breast cancer cells are localized and noninvasive in the breast tissue.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: September 30, 2008
    Assignees: The Regents of the University of California, California Pacific Medical Center
    Inventors: Pierre-Yves Desprez, Judith Campisi
  • Peptide epitopes common to antigens of the same multigene family
    Patent number: 7419669
    Abstract: The invention relates to the production of peptide epitopes common to a plurality of antigens of the same multigene family, said epitopes containing at least one common pentapeptide sequence preceded by three amino acids at the N-terminal end and optionally followed by one or two amino acids at the C-terminal end. The invention also relates to polynucleotides coding for said epitopes. Said peptides and polynucleotides can be especially used in anti-tumour immunotherapy.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: September 2, 2008
    Assignees: Institut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale
    Inventors: Kostas Kosmatopoulos, Stephanie Graff-Dubois
  • TAG-1 and TAG-2 proteins and uses thereof
    Patent number: 7413894
    Abstract: The present invention is directed to a newly discovered gene family with multiple isoforms, designated TAG-1, TAG-2a, TAG-2b, TAG-2c, and TAG-3, nucleic acid sequences encoding those proteins, and antibodies generated against said proteins. The genes, proteins, and peptides described herein may be used as diagnostic indicators of the presence of cancer and/or used in therapeutics to treat cancer.
    Type: Grant
    Filed: July 1, 2004
    Date of Patent: August 19, 2008
    Assignee: University of Virginia Patent Foundation
    Inventors: Kevin T. Hogan, Craig L. Slingluff, Jr.
  • In vivo activation of tumor-specific cytotoxic T cells
    Patent number: 7402314
    Abstract: The present invention relates to methods and compositions of activating cytotoxic T lymphocytes (CTLs) in vivo with specificity for particular antigenic peptides, and to methods and compositions of using activated CTLs in vivo for the treatment of a variety of disease conditions. In some preferred embodiments, the invention provides methods of employing a polypeptide of the amino acid sequence VMAGVGSPYV to specifically activating CTLs in subjects having a breast cancer overexpressing a Her-2/Neu protein, and methods of using the polypeptide to treat such subjects.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: July 22, 2008
    Assignee: The Scripps Research Institute
    Inventor: Linda A. Sherman
  • Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor
    Patent number: 7399827
    Abstract: PAGE-4 is a gene preferentially expressed in normal male and female reproductive tissues, prostate, testis, fallopian tube, uterus and placenta, as well as in prostate cancer, testicular cancer and uterine cancer. This expression pattern makes it a target for diagnosis and for vaccine based therapy of neoplasms of prostate, testis and uterus. The invention provides immunogenic compositions comprising PAGE-4 protein or immunogenic peptides thereof, methods of inhibiting the growth of malignant cells expressing PAGE-4, and methods of inducing an enhanced immune response to PAGE-4-expressing cancers.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: July 15, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira Pastan, Ulrich Brinkmann, George Vasmatzis, Byungkook Lee
  • Prostate-specific polypeptide pamp and encoding nucleic acid molecules
    Patent number: 7393921
    Abstract: The present invention relates to novel prostate specific nucleic acid molecules and polypeptides and related methods for diagnosing or predicting susceptibility to a prostate neoplastic condition.
    Type: Grant
    Filed: December 4, 2000
    Date of Patent: July 1, 2008
    Assignee: Institute for Systems Biology
    Inventor: Biaoyang Lin
  • Modulators of intracellular inflammation, cell death and cell survival pathways
    Patent number: 7374909
    Abstract: A B1 protein, its isoforms, analogs, fragments and derivatives, DNA encoding it and recombinant production are provided. The protein is useful in the modulation of intracellular inflammation, cell death and/or cell survival pathways.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: May 20, 2008
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Mark Boldiin, Nikolai Malinin
  • Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
    Patent number: 7364862
    Abstract: The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: April 29, 2008
    Assignee: diaDexus, Inc.
    Inventors: Shujath M. Ali, Yongming Sun, Susana Salceda, Herve Recipon, Robert Cafferkey
  • Methods to inhibit growth of prostate cancer cells
    Patent number: 7361338
    Abstract: A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: April 22, 2008
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Mary Faris, Arthur B. Raitano, Robert Kendall Morrison, Douglas Saffran, Wangmao Ge, Pia M. Challita-Eid
  • Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
    Patent number: 7354587
    Abstract: Humoral and cellular immune responses against tumor cells and infectious agents are induced in a mammal using a vaccine comprising immunoconjugates that comprise antibodies and anti-idiotype antibodies that mimic an epitope of an antigen that is associated with a tumor or an infectious agent. These immunoconjugates also comprise a peptide that contains an epitope of a tumor associated antigen or infectious agent antigen, a peptide that contains a minimal recognition unit of an anti-idiotype antibody, or a peptide that induces a strong major histocompatibility complex-restricted immune response. Antibodies and cytokines also may be used to amplify the immune cascade.
    Type: Grant
    Filed: December 22, 1995
    Date of Patent: April 8, 2008
    Assignee: Immunomedics, Inc.
    Inventor: Hans J. Hansen
  • Antibodies to G protein-coupled receptor
    Patent number: 7351583
    Abstract: A novel gene (designated PHOR-1) that is highly over-expressed in prostate and other cancers and its encoded protein are described. PHOR-1 is a G protein-coupled receptor with homology to receptors involved in olfaction. PHOR-1 in normal human tissues is restricted to prostate, and this gene is highly over-expressed in prostate cancer as well as in cancers of the kidney, uterus, cervix, stomach and rectum. Consequently, PHOR-1 provides a diagnostic and/or therapeutic target for prostate cancer.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: April 1, 2008
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Daniel E. H. Afar, Aya Jakobovits, Mary Faris, Rene S. Hubert, Steven Chappell Mitchell, Douglas Saffran
  • Mage C2 antigenic peptides and uses thereof
    Patent number: 7348007
    Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: March 25, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Aline Van Pel, Daniele Godelaine, Javier Carrasco, Francis Brasseur, Thierry Boon-Falleur
  • cDNA encoding a gene BOG (B5T over-expressed gene) and its protein product
    Patent number: 7342099
    Abstract: Nucleic acids that encode novel polypeptides, designated in the present application as “BOG” (B5T Over-expressed Gene) are provided. BOG binds to pRb and is over-expressed in a number transformed rat liver epithelial (RLE) cell lines resistant to the growth inhibitory effect of TGF-?1 as well as in primary liver tumors. Compositions including BOG chimeras, nucleic acids encoding BOG and antibodies to BOG are also provided. Methods of using BOG to modulate pRb-protein interactions and to alter cellular phenotype are further provided.
    Type: Grant
    Filed: February 5, 2004
    Date of Patent: March 11, 2008
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Snorri S. Thorgeirsson, Joseph T. Woitach, Minghuang Zhang
  • Methods and compositions for diagnosing breast cancer
    Patent number: 7332287
    Abstract: Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.
    Type: Grant
    Filed: July 9, 2002
    Date of Patent: February 19, 2008
    Assignee: The Regents of the University of Michigan
    Inventor: Paul R. Ervin, Jr.
  • Fusion genes associated with acute megakaryoblastoc leukemias
    Patent number: 7329744
    Abstract: The invention relates to human nucleotide sequences which occur as a result of the t(1;22)(p13;q13) chromosomal translocation event which is known to occur almost invariable in young children with acute megakaryoblastic leukemia. The translocation results in the formation of fusion genes which encode fusion proteins. The invention provides the nucleotide sequences of transcripts of the fusion genes and the amino acid sequences of the fusion proteins encoded thereby. Also provided are methods for detecting the t(1, 22) translocation, for identifying agents capable of binding to the fusion protein and for identifying agents useful for treating patients with acute megakaryoblastic leukemia.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: February 12, 2008
    Assignees: St. Jude Children's Research Hospital Inc., The Hospital for Sick Children
    Inventors: Stephan W. Morris, Zhigui Ma, Johann K. Hitzler
  • MAGE-A4 antigenic peptides and uses thereof
    Patent number: 7311914
    Abstract: The invention provides antigenic peptides derived from MAGE polypeptides and presented by HLA-B37 molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: December 25, 2007
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Yi Zhang, Vincent Stroobant, Vincenzo Russo, Thierry Boon-Falleur, Pierre van der Bruggen